Navigation Links
Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
Date:11/12/2009

BALTIMORE, Nov. 12 /PRNewswire-FirstCall/ -- Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, has announced that two of its studies regarding its application in oncology drug development and personalized medicine have been selected for a poster and oral presentation at the upcoming AACR-EORTC conference in Boston.

A poster will be presented by Dr. Elizabeth Bruckheimer, Champions' Vice President for Scientific Operations, which will detail the Biomerk Tumorgraft(TM) platform and its characterization. Together the results demonstrate that by maintaining the fundamental genotypic features of the original tumor along with the stromal and cancer stem cell components, the Biomerk Tumorgraft enables identification of the most promising development path for a compound in terms of indication, drug combination, and target patient populations. The platform also has the potential to identify gene pathways of response and resistance as well as prognostic molecular biomarkers. The banking and characterization efforts are performed in collaboration with South Texas Accelerated Research Therapeutics (START).

"The predictive power of the Biomerk Tumorgraft platform is very exciting," said Dr. Bruckheimer. "Application of our models to translational drug development is demonstrating great promise in streamlining the development path of our biotech and pharma partners by giving them a more focused, accelerated and higher probability translational path in clinical trials. Additionally, we are using our platform to build our own oncology pipeline which we expect to yield improved clinical development success rates. We believe that this platform will continue to change the way in which oncology drugs are developed, and oncology pa
'/>"/>

SOURCE Champions Biotechnology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
2. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
3. Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team
4. Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share
5. Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs
6. Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results
7. Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results
8. Champions Biotechnology, Inc. Establishes UK Subsidiary and Retains General Manager to Expand Its Personalized Oncology Business
9. Champions Biotechnology Partners with Do-Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft(TM) Testing
10. Champions Biotechnology Reports Fiscal 2009 Full-Year Financial Results
11. Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Victoria, Australia (PRWEB) September 02, 2014 ... provide a cure for chronic tinnitus are seeking support ... run on the Indiegogo platform ( http://igg.me/at/tinaway ), was ... to be a therapeutic ‘mHealth’ app and is based ... brainchild of a team of biomedical and software engineers, ...
(Date:8/31/2014)... -- Wockhardt Limited today announces a major boost to ... two of its drugs, WCK 771 and WCK 2349, ... from U.S. Food & Drug Administration (FDA).  QIDP status ... have a high degree of unmet need in their ... (a top U.S. government health and safety body).  QIDP ...
(Date:8/30/2014)... Dallas, TX (PRWEB) August 31, 2014 ... Industry is a professional and in-depth study on ... industry in Global and China. , The report ... definitions, applications and industry chain structure. Global market ... with a focus on history, developments, trends and ...
(Date:8/29/2014)... August 29, 2014 According to a new ... the global orthobiologics market was valued at USD 3,754.6 million ... USD 5,519.9million in 2019at a CAGR of 5.9% from 2013 ... years and above is afflicted by bone and joint disorders, ... year 2020. This has and will continue to increase the ...
Breaking Biology Technology:tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 2tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 3tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 4tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 5U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 2Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 3Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3
... , CAMBRIDGE, Mass., Aug. 11 Tolerx, ... therapies for immune-mediated diseases, today announced changes to the protocol for its ... of otelixizumab, a targeted T cell immunomodulator, in patients with new-onset autoimmune ... urable Response Therapy E valuation F or E arly ...
... WALTHAM, Mass., Aug. 11 Decision Resources, one of the world,s ... that the entry and uptake of premium-priced biologics will drive the ... $420 million in 2008 to nearly $2 billion in 2018. , ... Lupus Erythematosus finds that the primary drivers of market growth ...
... , , ... that BD Biosciences, a segment of BD (Becton, Dickinson and ... Pathway Navigation technologies into its new website. By leveraging ... its research customers to quickly and easily identify products and ...
Cached Biology Technology:Tolerx Announces Amendment to Phase 3 DEFEND Protocol 2Tolerx Announces Amendment to Phase 3 DEFEND Protocol 3Biologic Agents Will Drive the Systemic Lupus Erythematosus Drug Market to More Than Quadruple to Nearly $2 Billion in 2018 2Ingenuity's Technology Powers BD Cell Pathways Tool on New BD Biosciences Website 2
(Date:8/29/2014)... at UC Davis have made some surprising discoveries ... Studying simian immunodeficiency virus (SIV), the team found ... cells are early responders to viral invasion and ... a cytokine called interleukin-1 beta (IL-1β). , ... causes breakdown of the gut epithelium that provides ...
(Date:8/29/2014)... about what genetic changes transform wild animals into domesticated ... is a University of Montana assistant professor, has made ... of the brain and the nervous system were particularly ... 28 in Science and gives answers to ... ., The domestication of animals and plants, a prerequisite ...
(Date:8/29/2014)... understand how the repeated climatic shifts over the ... of genetic diversity, a team of researchers led ... Ana Carnaval developed a new biodiversity metric called ... which the genetic variation within species is restricted ... professor of biology, and 14 other researchers from ...
Breaking Biology News(10 mins):The early cost of HIV 2New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3CCNY team defines new biodiversity metric 2
... proteins are the bad guys that help bacterial pathogens do ... immune system. In essence, they knock down the front ... Now, researchers at the University of California, San Diego (UCSD) ... an effector protein called YpkA, one of several effectors of ...
... could soon be roaming our pastures, reports Cath O’Driscoll in ... in New Zealand have discovered that some cows have genes ... and plan to use this information to breed herds of ... plan to breed commercial herds producing milk with the unique ...
... H5N1 strain of avian influenza may hold the key to ... of researchers. In a study published today in the open ... antibodies taken from avian flu survivors in Vietnam can be ... virus in culture vitro and in mice. , The H5N1 ...
Cached Biology News:How plague-causing bacteria disarm host defense 2Skimmed milk -- Straight from the cow 2Avian influenza survivors' antibodies effective at neutralising H5N1 strain 2
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
... Quality ISO 9001:2000 Certified ... All Precedures Validated, SOP's Training ... Process for All Procedures GLP Documentation Upon ... one stop shopping point for all your ...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Request Info...
Biology Products: